Circulating miR-let7a levels predict future diagnosis of chronic thromboembolic pulmonary hypertension

Franziska Kenneweg,Lukas Hobohm,Claudia Bang,Shashi K. Gupta,Ke Xiao,Sabrina Thum,Vincent Ten Cate,Steffen Rapp,Gerd Hasenfuß,Philipp Wild,Stavros Konstantinides,Rolf Wachter,Mareike Lankeit,Thomas Thum

DOI: https://doi.org/10.1038/s41598-024-55223-1

IF: 4.6

2024-02-25

Scientific Reports

Abstract:Distinct patterns of circulating microRNAs (miRNAs) were found to be involved in misguided thrombus resolution. Thus, we aimed to investigate dysregulated miRNA signatures during the acute phase of pulmonary embolism (PE) and test their diagnostic and predictive value for future diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH). Microarray screening and subsequent validation in a large patient cohort (n = 177) identified three dysregulated miRNAs as potential biomarkers: circulating miR-29a and miR-720 were significantly upregulated and miR-let7a was significantly downregulated in plasma of patients with PE. In a second validation study equal expression patterns for miR-29a and miR-let7a regarding an acute event of recurrent venous thromboembolism (VTE) or deaths were found. MiR-let7a concentrations significantly correlated with echocardiographic and laboratory parameters indicating right ventricular (RV) dysfunction. Additionally, circulating miR-let7a levels were associated with diagnosis of CTEPH during follow-up. Regarding CTEPH diagnosis, ROC analysis illustrated an AUC of 0.767 (95% CI 0.54–0.99) for miR-let7a. Using logistic regression analysis, a calculated patient-cohort optimized miR-let7a cut-off value derived from ROC analysis of ≥ 11.92 was associated with a 12.8-fold increased risk for CTEPH. Therefore, miR-let7a might serve as a novel biomarker to identify patients with haemodynamic impairment and as a novel predictor for patients at risk for CTEPH.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to explore the expression patterns of circulating microRNAs (miRNAs) in patients with acute pulmonary embolism (PE) and to evaluate the value of these miRNAs as biomarkers for the diagnosis and prediction of chronic thromboembolic pulmonary hypertension (CTEPH). Specifically, the researchers hope to identify abnormally expressed miRNAs in patients with acute PE to investigate whether these miRNAs can predict the future diagnosis of CTEPH.

The background of the study indicates that acute pulmonary embolism is a common vascular disease that can lead to severe short-term and long-term complications, including recurrence, chronic thromboembolic pulmonary hypertension (CTEPH), and death. CTEPH is a rare but fatal disease with poor prognosis if left untreated. In recent years, research on miRNAs as novel biomarkers has increased, and their diagnostic and prognostic value in various diseases has been confirmed. However, little is known about the miRNA profiles in patients with acute PE and CTEPH.

Therefore, this study aims to discover miRNAs associated with acute PE by screening and validating miRNA expression patterns in a large patient cohort and to evaluate the potential role of these miRNAs in predicting the diagnosis of CTEPH. The study ultimately identified three significantly abnormally expressed miRNAs: miR-29a and miR-720 were significantly upregulated, while miR-let7a was significantly downregulated. Further analysis showed that miR-let7a levels were associated with indicators of right ventricular dysfunction and were significantly related to the diagnosis of CTEPH during follow-up, suggesting that miR-let7a may serve as a novel biomarker for identifying patients at risk of hemodynamic impairment and predicting the future risk of developing CTEPH.